Copyright
©The Author(s) 2016.
World J Gastroenterol. Jan 21, 2016; 22(3): 1321-1330
Published online Jan 21, 2016. doi: 10.3748/wjg.v22.i3.1321
Published online Jan 21, 2016. doi: 10.3748/wjg.v22.i3.1321
Table 1 Eligibility criteria for inclusion
Adults |
Diagnosis of IBD, according to international guidelines |
English language |
Prevalence and/or diagnostics CMV infection or intestinal disease reported |
Minimal sample size 10 patients |
Table 2 Prevalence by definition of cytomegalovirus-infection
Definition | Studies, n | Median | Range |
Antigenemia[17-21] | 5 | 32% | 6%-34% |
Tissue PCR[22-25] | 4 | 11% | 1%-32% |
IHC1[26-29] | 4 | 13% | 9%-23% |
HE[30-32] | 3 | 17% | 5%-36% |
HE or IHC[33,34] | 2 | 8% | 5%-11% |
HE and IHC[35,36] | 2 | 19% | 12%-27% |
IgM or HE or IHC2[37,38] | 2 | 9% | 5%-13% |
Antigenemia or Tissue PCR[39] | 1 | NA | NA |
Serum PCR[40] | 1 | 84% | - |
(HE and IHC) or tissue PCR[41] | 1 | 4% | - |
Tissue PCR 10 copies/µg; OR histology OR Antigenemia[42] | 1 | 54% | - |
Antigenemia (2 tests: C7-HRP OR C10/C11) OR histology[43] | 1 | 9% | - |
Antigenemia or blood PCRquantitative[44] | 1 | 36% | - |
IgM or serum PCR or HE[45] | 1 | 78% | - |
IgM or tissue PCRqualitative or HE[46] | 1 | 16% | - |
IgG and (blood culture, antigenemia or histology or IgM or urine culture)[47] | 1 | 6% | - |
IgM or serum PCRqualitative or feces PCR[48] | 1 | 5% | - |
Inclusions: HE[49] | 1 | 13% | - |
Active infection: tissue PCR[50] | 1 | 13% | - |
Active replication: (HE or IHC) and antigenemia[51] | 1 | 36% | - |
Blood dissemination: (viremia, antigenemia, RNAemia) or (viremia or tissue culture)[52] | 1 | 16% | - |
Total: 21 | Total: 36 |
Table 3 Prevalence by definition of cytomegalovirus-intestinal disease
Definition | Studies, n | Median | Range |
HE or IHC1,2[38,44,53,54] | 4 | 6% | 2%-29% |
HE[20,55] | 2 | 9% | 0%-17% |
Tissue PCRquantitative > 10 copies/mg[56,57] | 2 | 34% | 30%-38% |
Serology and (IHC or antigenemia or serum PCR or tissue PCR)[58] | 1 | 6% | - |
IHC[59] | 1 | 0% | - |
HE or IHC or tissue PCR[51] | 1 | 33% | - |
(Pp65 antigenemia or tissue PCRquantitative) and IHC and intestinal symptoms[39] | 1 | NA3 | - |
IHC positive when inflammation present[52] | 1 | 1% | - |
Total: 8 | Total: 13 |
Table 4 Prevalence by definition of cytomegalovirus-reactivation
Table 5 Test characteristics different diagnostic tools for cytomegalovirus
Test | Pro | Con | Sens | Spec |
Serology | Fast, quantification possible | Systemic, not proving intestinal disease; | 98%-100% | 96%-99% |
Antigenemia | Fast, quantification possible | Systemic, not proving intestinal disease labor intensive | 60%-100% | 83%-100% |
Serum PCR | Fast, quantification possible | Systemic, not proving intestinal disease | 65%-100% | 40%-94% |
HE Histology (gold standard?) | Specific, proofs intestinal disease | Slow; low sensitivity | 10%-87% | 92%-100% |
Histology with IHC | Specific, proofs intestinal disease | Slow | 93% | 92%-100% |
Tissue PCR | Quantification possible | Cut-off point unclear, uncertain clinical significance | 65%-100% | 40%-100% |
Stool PCR | Quantification possible | Little experience | 83%% | 93% |
Viral Culture | Very specific | Very slow | 45%-78% | 89%-100% |
Rapid Vial culture | Very specific | Little experience | 68%-100% | 89%-100% |
- Citation: Römkens TE, Bulte GJ, Nissen LH, Drenth JP. Cytomegalovirus in inflammatory bowel disease: A systematic review. World J Gastroenterol 2016; 22(3): 1321-1330
- URL: https://www.wjgnet.com/1007-9327/full/v22/i3/1321.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i3.1321